Kiseleva E S, Pitskhelauri V G, Trakhtenberg A K, Daryalova S L, Kasyanenko I V, Zakharchenkov A V, Lebedev V A, Zvekotkina L S, Glagolev A N, Bidyak I P
Neoplasma. 1983;30(5):573-80.
In this study there is presented a comparative analysis of immediate results after radiotherapy and combined treatment (radio- and chemotherapy) in 174 patients with highly differentiated inoperable lung cancer. The data were provided by participants of a joint investigation in some CMEA member countries (Hungary, USSR, Czechoslovakia) during the period of 1976 to 1980. In the randomized study radiotherapy (a total dose of 60 Gy) was applied in 98 patients, radiotherapy with chemotherapy (methotrexate and 5-fluorouracil) was applied in 76 patients. The comparative analysis showed that the employment of complementary chemotherapy tend to improve the immediate therapeutic effects. In the case of highly differentiated planocellular carcinoma a pronounced positive effect was seen in 48.6% of patients as compared to the 31.2% of those treated with radiotherapy alone. Nevertheless, with respect to survival rate prolongation, these differences are not manifested in favor of the combined method of treatment. After a conservative treatment (radiotherapy and radiotherapy in combination with chemotherapy) of patients with differentiated types of inoperable lung cancer there was a one-year survival rate of 55.7%, 17.27% of the patients survived for 2 years, and 8.55% for 3 years. In radiotherapy applied alone as in the combined method as well, a direct dependence of survival rate prolongation on immediate therapeutical effects was detected. For more than 1 year survived 49 patients (73.1%) out of 67 exhibiting pronounced immediate effects, and for 3 years survived 8 patients out of 9.
本研究对174例高分化不可切除肺癌患者放疗及综合治疗（放疗与化疗联合）后的近期疗效进行了对比分析。数据由一些经互会成员国（匈牙利、苏联、捷克斯洛伐克）的联合调查参与者于1976年至1980年期间提供。在随机研究中，98例患者接受放疗（总剂量60Gy），76例患者接受放疗联合化疗（甲氨蝶呤和5-氟尿嘧啶）。对比分析表明，辅助化疗有助于提高近期治疗效果。对于高分化扁平细胞癌，联合治疗组48.6%的患者有明显阳性效果，而单纯放疗组这一比例为31.2%。然而，就生存率延长而言，这些差异并未显示联合治疗方法更具优势。对高分化不可切除肺癌患者进行保守治疗（放疗以及放疗联合化疗）后，一年生存率为55.7%，17.27%的患者存活2年，8.55%的患者存活3年。在单纯放疗组以及联合治疗组中，均检测到生存率延长与近期治疗效果存在直接相关性。67例近期疗效显著的患者中，49例（73.1%）存活超过1年，9例患者中有8例存活3年。
